Trader sentiment remains evenly distributed across market cap bins and the no-IPO-before-June-2026 outcome at 50% implied probabilities each, highlighting intense uncertainty for Encore Medical's (EMI) imminent initial public offering amid volatile medtech sector dynamics. December 2025 pricing terms set 3 million shares at $5.00, implying a fully diluted $49 million market cap squarely in the 45M–50M range, yet traders price in execution risks given $1.88 million trailing-12-month revenue and -$1.23 million net loss from early commercialization of transcatheter cardiac defect implants used in 35,000 patients. Differentiators include minimally invasive positioning versus incumbents like Edwards Lifesciences, but swing factors hinge on roadshow reception, biotech index trends, and final prospectus adjustments ahead of the targeted April 15 NYSE MKT debut.
Resumen experimental generado por IA con datos de Polymarket · Actualizado<45M 50%
55M+ 50%
No IPO before June 2026 50%
50M–55M 49%
NUEVO
NUEVO
15 abr 2026
<45M
50%
45M–50M
48%
50M–55M
49%
55M+
50%
No IPO before June 2026
50%
<45M 50%
55M+ 50%
No IPO before June 2026 50%
50M–55M 49%
NUEVO
NUEVO
15 abr 2026
<45M
$0 Vol.
50%
45M–50M
$1 Vol.
48%
50M–55M
$1 Vol.
49%
55M+
$0 Vol.
50%
No IPO before June 2026
$0 Vol.
50%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader sentiment remains evenly distributed across market cap bins and the no-IPO-before-June-2026 outcome at 50% implied probabilities each, highlighting intense uncertainty for Encore Medical's (EMI) imminent initial public offering amid volatile medtech sector dynamics. December 2025 pricing terms set 3 million shares at $5.00, implying a fully diluted $49 million market cap squarely in the 45M–50M range, yet traders price in execution risks given $1.88 million trailing-12-month revenue and -$1.23 million net loss from early commercialization of transcatheter cardiac defect implants used in 35,000 patients. Differentiators include minimally invasive positioning versus incumbents like Edwards Lifesciences, but swing factors hinge on roadshow reception, biotech index trends, and final prospectus adjustments ahead of the targeted April 15 NYSE MKT debut.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercado abierto: Apr 3, 2026, 7:59 PM ET
Volumen
$2Fecha de finalización
15 abr 2026Mercado abierto
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader sentiment remains evenly distributed across market cap bins and the no-IPO-before-June-2026 outcome at 50% implied probabilities each, highlighting intense uncertainty for Encore Medical's (EMI) imminent initial public offering amid volatile medtech sector dynamics. December 2025 pricing terms set 3 million shares at $5.00, implying a fully diluted $49 million market cap squarely in the 45M–50M range, yet traders price in execution risks given $1.88 million trailing-12-month revenue and -$1.23 million net loss from early commercialization of transcatheter cardiac defect implants used in 35,000 patients. Differentiators include minimally invasive positioning versus incumbents like Edwards Lifesciences, but swing factors hinge on roadshow reception, biotech index trends, and final prospectus adjustments ahead of the targeted April 15 NYSE MKT debut.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$2Fecha de finalización
15 abr 2026Mercado abierto
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Trader sentiment remains evenly distributed across market cap bins and the no-IPO-before-June-2026 outcome at 50% implied probabilities each, highlighting intense uncertainty for Encore Medical's (EMI) imminent initial public offering amid volatile medtech sector dynamics. December 2025 pricing terms set 3 million shares at $5.00, implying a fully diluted $49 million market cap squarely in the 45M–50M range, yet traders price in execution risks given $1.88 million trailing-12-month revenue and -$1.23 million net loss from early commercialization of transcatheter cardiac defect implants used in 35,000 patients. Differentiators include minimally invasive positioning versus incumbents like Edwards Lifesciences, but swing factors hinge on roadshow reception, biotech index trends, and final prospectus adjustments ahead of the targeted April 15 NYSE MKT debut.
Resumen experimental generado por IA con datos de Polymarket · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes